/
RSS Feed
Audio Journal of Oncology
Patients with Desmoplastic Melanoma Were Exceptional Responders to Single Agent Pembrolizumab
LOS ANGELES, CA—Single agent immunotherapy with the anti-programmed death-1 (PD-1) agent pembrolizumab resulted in markedly high melanoma-specific survival rates among patients with either resectable or metastatic desmoplastic melanoma in a study reported to the American Association for Cancer Research 2025 Immno Oncology conference.
Lead researcher Kari L Kendra MD PhD, Director of the Cutaneous Oncology Program and Chair of the Melanoma Disease Specific Committee at Ohio State University’s Wexner Medical Center in Columbus, OH gave the Audio Journal of Oncology’s Peter Goodwin the latest details:
